These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21867368)

  • 1. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
    Foyil KV; Kennedy DA; Grove LE; Bartlett NL; Cashen AF
    Leuk Lymphoma; 2012 Mar; 53(3):506-7. PubMed ID: 21867368
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
    Ordemann R; Stöhlmacher J; Beuthien-Baumann B; Platzek I; van den Hoff J; Kroschinsky F; Middeke JM; Platzbecker U; Zietz C; Bornhäuser M; Ehninger G
    Ann Hematol; 2013 Jan; 92(1):125-7. PubMed ID: 22820970
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
    Kawamoto K; Suzuki T; Kasami T; Kiryu M; Sone H; Miyoshi H; Ohshima K; Takizawa J
    Hematol Oncol; 2019 Apr; 37(2):212-214. PubMed ID: 30394560
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment strategy of Hodgkin lymphoma].
    Nagai H
    Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults.
    Fanin R; Silvestri F; Geromin A; Cerno M; Infanti L; Zaja F; Barillari G; Savignano C; Rinaldi C; Damiani D; Baccarani M
    Leuk Lymphoma; 1997 Jan; 24(3-4):369-77. PubMed ID: 9156668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
    Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
    Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
    Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
    Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
    Fetscher S; Lübbert M; Kanz L; Behringer D; Finke J; Mertelsmann R; Lange W
    Bone Marrow Transplant; 1997 Mar; 19(5):527-8. PubMed ID: 9052926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intensive treatment of T-cell-rich B lymphoma].
    Azaceta G; Palomera L; Varo MJ; Soria J
    Sangre (Barc); 1998 Feb; 43(1):94-5. PubMed ID: 9577190
    [No Abstract]   [Full Text] [Related]  

  • 14. First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature.
    Chernova NG; Zvonkov EE; Badmazhapova DS; Sinitsyna MN; Grebenyuk LA; Sidorova YV; Kostina IE; Kovrigina AM; Obukhova TN; Sudarikov AB; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):77-81. PubMed ID: 30701926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
    Popescu RA; Wotherspoon AC; Cunningham D
    Bone Marrow Transplant; 1998 Jul; 22(1):103-6. PubMed ID: 9678804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
    Kaiser U; Uebelacker I; Abel U; Birkmann J; Trümper L; Schmalenberg H; Karakas T; Metzner B; Hossfeld DK; Bischoff HG; Franke A; Reiser M; Müller P; Mantovani L; Grundeis M; Rothmann F; von Seydewitz CU; Mesters RM; Steinhauer EU; Krahl D; Schumacher K; Kneba M; Baudis M; Schmitz N; Pfab R; Köppler H; Parwaresch R; Pfreundschuh M; Havemann K
    J Clin Oncol; 2002 Nov; 20(22):4413-9. PubMed ID: 12431962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
    McQuaker IG; Haynes AP; Iqbal A; Russell NH
    Bone Marrow Transplant; 1996 Jul; 18(1):263-4. PubMed ID: 8832036
    [No Abstract]   [Full Text] [Related]  

  • 18. Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
    Pellegrini C; Maglie R; Argnani L; Pileri S; Zinzani PL
    Hematol Oncol; 2016 Mar; 34(1):49-51. PubMed ID: 25243375
    [No Abstract]   [Full Text] [Related]  

  • 19. Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
    Wang B; Ren C; Zhang W; Ma X; Xia B; Sheng Z
    Hematol Oncol; 2013 Mar; 31(1):29-33. PubMed ID: 22488650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    García-Sanz R; González-López TJ; Vázquez L; Hermida G; Graciani IF; San Miguel JF
    Eur J Haematol; 2010 Mar; 84(3):266-70. PubMed ID: 19912314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.